ActivBiotics Cuts IPO Forecast

ActivBiotics Inc., a Lexington, Mass.-based developer of antibacterials for high-value chronic and infectious diseases, has reduced its IPO pricing forecast from $12-$14 per share to $8-$10 per share. It still plans to offer 4 million common shares, and trade on the Nasdaq under ticker symbol ACTV. HSBC is serving as lead underwriter. ActivBiotitics has raised around $52 million in total VC funding since its 1996 inception, from firms like HealthCare Ventures, BioVentures Inv*stors, MDS Health Ventures, Delphi Ventures, China Development Industrial Bank, Canadian Medical Discoveries Fund, New England Partners and Vengrowth.< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />